October 15, 2021

Medical Trend

Medical News and Medical Resources

Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients

Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients

Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients



 

Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients. 

Tukysa (Tucatinib) and its parent drug ONT-993 have been detected in CSF and are directly proportional to the level in plasma.

The results of a phase 2 study (NCT03501979) examined the combined treatment of tucatinib (Tukysa), trastuzumab (Herceptin) and capecitabine (Xeloda) in HER2-positive breast cancer patients with pial metastases .

 

The Tukysa+Herceptin+Xeloda combination has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer.

This indication is suitable for patients with or without brain metastases. However, no studies have evaluated the efficacy of this combination in patients with brain metastases. Due to the aggressive nature of the disease, patients with brain metastases are usually excluded from clinical trials.

 

Pharmacokinetic analysis found that Tukysa (tucatinib) and its parent drug, ONT-993, were detected in the cerebrospinal fluid and were directly proportional to the level in plasma. There are 18 patients in the study, and hopefully it will increase to 30.

 

The combination therapy of tucatinib, trastuzumab and capecitabine has been approved by the FDA for the treatment of advanced metastatic HER2-positive breast cancer, as well as those diagnosed with brain metastases patient.

But no studies have really evaluated this combination in pia mater disease. In fact, in most clinical trials, leptomeningeal disease is often excluded from research due to its aggressiveness.

In this study, the first 15 patients were evaluated, and the pharmacokinetics in CSL and plasma were evaluated. It was found that Tukysa (Tucatinib) and its parent drug ONT-993 were both detected in CSF and were directly proportional to the level in plasma. This is the first study to evaluate tucatinib and its maternal metabolites in CSF.

 

Tukysa was detected in cerebrospinal fluid and plasma of HER2+BC patients

(source:internet, reference only)


Disclaimer of medicaltrend.org